On April 6, 2026, Oncolytics Biotech Inc. (the "Company") entered into an Open Market Sale Agreement (the "Sales Agreement") with Jefferies LLC (the "Agent"), pursuant to which the Company may offer and sell from time to time through or to the agent, acting as agent or principal, shares of the Company's common stock, par value $0.001 per share, having an aggregate offering price of up to $75.0 million (the "Shares").

 

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.